<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD class=bold-content width="5%"></TD><TD class=content width="95%">http://www.responsiblegambling.org/e-library_most_recent_details.cfm?intID=7194</TD></TR></TBODY></TABLE></TD></TR><TR><TD><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD class=content width=532 colSpan=3>
</TD></TR><TR><TD class=content width="5%"> </TD><TD class=bold-content width="20%"></TD><TD class=content width="75%"></TD></TR><TR><TD class=content> </TD><TD class=bold-content>Source:</TD><TD class=content>Kansas City Star</TD></TR><TR><TD class=content> </TD><TD class=bold-content>Published Date:</TD><TD class=content>Dec 14, 2004</TD></TR><TR><TD class=content colSpan=3>
</TD></TR><TR><TD class=content> </TD><TD class=bold-content vAlign=top width=532 colSpan=2></TD></TR><TR><TD class=content> </TD><TD class=content vAlign=top width=532 colSpan=2>The day is drawing near when compulsive gamblers might pop a pill to combat their self-destructive urges. San Diego-based Somaxon Pharmaceuticals Inc. appears to be the first U.S. firm to stake a formal claim on a treatment drug. The company recently announced it has obtained North American licensing rights to a Finnish firm's treatment for impulse control disorders using the drug nalmefene hydrochloride. </TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>
